Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis

Putranto, Johanes Nugroho Eko and Wardhana, Ardyan Prima and Noor, Yoga Alfian and Siahaan, Pirhot Lambok Marnala Yosua and Farabi, Makhyan Jibril Al (2021) Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis. F1000Research, 10. p. 1257. ISSN 2046-1402

PDF Ardyan Prima Wardhana_factor Xa.pdf Download (2MB)

Abstract

Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation. The present meta-analysis aimed to assess the effectiveness of factor Xa inhibitors for the management of venous thromboembolism (VTE), specifically in patients with cancer, as there were more randomized clinical trials (RCTs) available. Methods: The PubMed and Cochrane Library databases were systematically screened for all RCTs assessing factor Xa inhibitor efficacy for VTE management in cancer patients. Using RevMan 5.3, we performed a Mantel–Haenszel fixed-effects meta-analysis of the following outcomes: recurrent VTE, VTE events, and major bleeding rates. Results: We identified 11 studies involving 7,965 patients. Factor Xa inhibitors were superior in preventing VTE recurrence, compared to low-molecular-weight heparin (LMWH) (OR 0.60; 95% CI 0.45–0.80; P < 0.01) and vitamin K antagonists (VKA) (OR 0.51; 95% CI 0.33–0.78; P < 0.01). As prophylaxis, factor Xa inhibitors had a similar rate of VTE compared to VKAs (OR 1.08 [95% CI 0.31–3.77]; P = 0.90) and a lower rate compared to placebo (OR 0.54 [95% CI 0.35–0.81]; P < 0.01). Major bleeding rates were higher with factor Xa inhibitors than with LMWHs (OR 1.34 [95% CI 0.83–2.18]; P = 0.23), but significantly lower than VKAs (OR 0.71 [95% CI 0.55–0.92]; P < 0.01). Conclusions: Factor Xa inhibitors are effective for VTE management in patients with cancer; however, they are also associated with an increased bleeding risk compared to LMWH, but decreased when compared to VKA

Item Type:	Article
Uncontrolled Keywords:	bleeding, cancer, factor Xa inhibitor, oral anticoagulant, venous thromboembolism
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Medical
Depositing User:	ARDYAN PRIMA WARDHANA
Date Deposited:	13 Dec 2021 02:21
Last Modified:	22 Apr 2022 02:52
URI:	http://repository.ubaya.ac.id/id/eprint/40814

Actions (login required)

View Item